Evidence map›Paper›PMID 30464490›Full record

ArticleTherapeutics and clinical risk management2018

Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study.

Sara S McCoy, Zubin Mukadam, Keith C Meyer, Jeffrey P Kanne, Cristopher A Meyer, Maria D Martin, Emmanuel Sampene, Scott W Aesif, Laurie N Rice, Christie M Bartels

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics and clinical risk management, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 35 citations in OpenAlex.

  1. Mycophenolate and azathioprine in fibrotic interstitial lung disease.American journal of respiratory and critical care medicine · 2026
    Observational
  2. Article
  3. Article
  4. Review
  5. Interstitial pneumonia with autoimmune features: challenges and controversies.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Immunomodulatory treatment of interstitial lung disease.Therapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sara S McCoyDivision of Rheumatology, Department of Internal Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA, ssmccoy@medicine.wisc.edu.
Zubin MukadamDivision of Pulmonary and Critical Care, Department of Internal Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.
Keith C MeyerDivision of Pulmonary and Critical Care, Department of Internal Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA.
Jeffrey P KanneDepartment of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
Cristopher A MeyerDepartment of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
Maria D MartinDepartment of Radiology, University of Wisconsin, Madison, WI 53792-3252, USA.
Emmanuel SampeneDepartment of Biostatistics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Scott W AesifDepartment of Pathology, University of Wisconsin, Madison, WI 53792-3252, USA.
Laurie N RiceDepartment of Pulmonology, SSM Health Dean Medical Group, Madison, WI 53715, USA.
Christie M BartelsDivision of Rheumatology, Department of Internal Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705, USA, ssmccoy@medicine.wisc.edu.
University of Wisconsin–Madison · USDean Health Systems · US

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
NCATS NIH HHS UL1 TR002373
6 · The paper itself

Abstract

objectivesInternational experts recently characterized interstitial pneumonia with autoimmune features (IPAF) as a provisional diagnosis for patients with interstitial lung disease who have characteristics of autoimmune disease but do not meet criteria for a specific autoimmune disease. We describe clinical characteristics of IPAF patients and examine responses to mycophenolate as a therapy for IPAF.

methodsThis retrospective cohort included adult patients meeting European Respiratory Society/American Thoracic Society classification criteria for IPAF. Sociodemographic, clinical, and pulmonary function test data were abstracted for patients with and without mycophenolate treatment and followed longitudinally from interstitial lung disease diagnosis for change in pulmonary function test results.

resultsWe identified 52 patients who met criteria for IPAF. Of 52 IPAF patients, 24 did not receive mycophenolate and 28 did, with median time to mycophenolate treatment 22 months. Changes in FVC% and percentage predicted lung diffusion capacity for carbon monoxide (D

conclusionPatients with IPAF might benefit from mycophenolate therapy. Larger prospective clinical trials are needed to evaluate the efficacy of mycophenolate for patients who meet criteria for IPAF.

Indexed as

autoimmune diseaseconnective tissue diseaseinterstitial lung diseasemycophenolate

Identifiers

PMID30464490
PMCPMC6219314
OpenAlexW2899088846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.